Research programme: inflammasome inhibitors - IFM Therapeutics

Drug Profile

Research programme: inflammasome inhibitors - IFM Therapeutics

Alternative Names: NLRP antagonists - IFM therapeutics

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator IFM therapeutics
  • Class Anti-inflammatories; Antigouts; Hepatoprotectants; Small molecules
  • Mechanism of Action Immunomodulators; Inflammasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gout; Inflammatory bowel diseases; Non-alcoholic steatohepatitis

Most Recent Events

  • 09 Aug 2017 Preclinical trials in Gout in USA before August 2017 (IFM Therapeutics pipeline, August 2017)
  • 09 Aug 2017 Preclinical trials in Inflammatory bowel disease in USA before August 2017 (IFM Therapeutics pipeline, August 2017)
  • 09 Aug 2017 Preclinical trials in Non-alcoholic steatohepatitis in USA before August 2017 (IFM Therapeutics pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top